Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind randomized placebo-controlled repeat-dose otelixizumab trial in NOT1DM
2013-003296-34Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in autoimmune disease and diabetes mellitus type 1 (T1D) comparing Otelixizumab with Placebo (2 arms). Started Nov 2013; status: completed.
02
Drugs
otelixizumab
03
Conditions
autoimmune diseasediabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2013-003296-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003296-34.